The ØieTozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 10, 2011, Pages 1233-1243

  Stepensky, David ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Displacement of drug from plasma proteins; Pharmacokinetic modeling; Plasma protein binding; Volume of distribution

Indexed keywords

AMINOGLYCOSIDE; DIAZEPAM; INDOMETACIN; LIDOCAINE; PACLITAXEL; PHENYTOIN; PROPOFOL; DRUG;

ANALYTIC METHOD; CALCULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; REVIEW; SIMULATION; STEADY STATE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY; PHARMACEUTICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; TISSUE DISTRIBUTION;

ANIMALS; BIOPHARMACEUTICS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHYSICOCHEMICAL PHENOMENA; TISSUE DISTRIBUTION;

EID: 80053010082     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.613823     Document Type: Review

References (61)

1. Dominguez R. Studies of renal excretion of clearance: II. Volume of distribution. Proc Soc Exp Biol Med 1934;31:1146-50
2. Atkinson AJ Jr, Lalonde RL. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. Clin Pharmacol Ther 2007;82:3-6 (Pubitemid 46944206)
3. Hochhaus G, Barrett JS, Derendorf H. Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century. J Clin Pharmacol 2000;40:908-17
4. Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007;24:918-33 (Pubitemid 46675393)
5. Berezhkovskiy LM. A valid equation for the well-stirred perfusion limited physiologically based pharmacokinetic model that consistently accounts for the blood-tissue drug distribution in the organ and the corresponding valid equation for the steady state volume of distribution. J Pharm Sci 2010;99:475-85
6. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90
7. Gibaldi M, McNamara PJ. Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol 1978;13:373-80
8. Gibaldi M, Perrier D. Apparent volume of distribution. In: Pharmacokinetics. 2nd edition. Informa Healthcare; New York: 2007. p. 199-219
9. Oie S, Tozer TN. Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 1979;68:1203-5 (Pubitemid 10231273)
10. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45-73
11. Bjorkman S. Prediction of the volume of distribution of a drug: which tissue-plasma partition coefficients are needed? J Pharm Pharmacol 2002;54:1237-45
12. Poulin P, Theil FP. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 2009;98:4941-61
13. Berry LM, Roberts J, Be X, et al. Prediction of V(ss) from in vitro tissue-binding studies. Drug Metab Dispos 2010;38:115-21
14. Valko KL, Nunhuck SB, Hill AP. Estimating unbound volume of distribution and tissue binding by in vitro HPLC-based human serum albumin and immobilised artificial membrane-binding measurements. J Pharm Sci 2011;In press
15. Fagerholm U. Prediction of human pharmacokinetics-evaluation of methods for prediction of volume of distribution. J Pharm Pharmacol 2007;59:1181-90 (Pubitemid 47359896)
16. Wajima T, Fukumura K, Yano Y, et al. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state. J Pharm Pharmacol 2003;55:939-49 (Pubitemid 36916684)
17. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006;72:1-10 (Pubitemid 43795346)
18. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-21 (Pubitemid 34271114)
19. Lombardo F, Obach RS, Shalaeva MY, et al. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 2002;45:2867-76 (Pubitemid 34627657)
20. Hosea NA, Collard WT, Cole S, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009;49:513-33
21. Waters NJ, Lombardo F. Use of the Oie-Tozer model in understanding mechanisms and determinants of drug distribution. Drug Metab Dispos 2010;38:1159-65
22. Do Jones R, Jones HM, Rowland M, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 2011;In press
23. Stepensky D. Use of unbound volumes of drug distribution in pharmacokinetic calculations. Eur J Pharm Sci 2011;42:91-8
24. Aarons L. Kinetics of drug-drug interactions. Pharmacol Ther 1981;14:321-44 (Pubitemid 12167660)
25. Aarons LJ, Rowland M. Kinetics of drug displacement interactions. J Pharmacokinet Biopharm 1981;9:181-90 (Pubitemid 11054340)
26. Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst 1999;16:571-639 (Pubitemid 30084602)
27. Hammarlund-Udenaes M. Active-site concentrations of chemicals - are they a better predictor of effect than plasma/ organ/tissue concentrations? Basic Clin Pharmacol Toxicol 2010;106:215-20
28. Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 2010;99:1107-22
29. Berezhkovskiy LM. On the influence of protein binding on pharmacological activity of drugs. J Pharm Sci 2010;99:2153-65
30. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 2006;33:227-79 (Pubitemid 44020382)
31. Danhof M, de Jongh J, De Lange EC, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007;47:357-400
32. Alvan G, Paintaud G, Wakelkamp M. The efficiency concept in pharmacodynamics. Clin Pharmacokinet 1999;36:375-89 (Pubitemid 29261512)
33. Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996;30:445-62 (Pubitemid 26175754)
34. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 2007;377:1-13 (Pubitemid 44920213)
35. Pilari S, Huisinga W. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn 2010;37:365-405
36. Poulin P, Ekins S, Theil FP. A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol 2011;250:194-212
37. Wada DR, Drover DR, Lemmens HJM. Determination of the distribution volume that can be used to calculate the intravenous loading dose. Clin Pharmacokinet 1998;35:1-7 (Pubitemid 28318959)
38. Berezhkovskiy LM. The connection between the steady state (Vss) and terminal (Vbeta) volumes of distribution in linear pharmacokinetics and the general proof that Vbeta Vss. J Pharm Sci 2007;96:1638-52 (Pubitemid 46953778)
39. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-58
40. Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 2005;44:331-47 (Pubitemid 40663681)
41. Rowland M, Tozer TN. Dose and time dependencies. In: Clinical pharmacokinetics: concepts and applications. 3rd edition. Lippincott Williams & Wilkins; Philadelphia; 1995. p. 394-423
42. Roberts DM, Buckley NA. Pharmacokinetic considerations in clinical toxicology: clinical applications. Clin Pharmacokinet 2007;46:897-939 (Pubitemid 47548642)
43. Hoffman A, Stepensky D, Ezra A, et al. Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharm 2001;220:1-11 (Pubitemid 32476836)
44. Karlsson MO, Molnar V, Freijs A, et al. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999;27:1220-3 (Pubitemid 29463611)
45. Craig WA. Pharmacokinetic/ pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10,quiz 1-2
46. Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 2010;37:25-47
47. Harashima H, Mamiya M, Yamazaki M, et al. Kinetic modeling of ouabain tissue distribution based on slow and saturable binding to Na,K-ATPase. Pharm Res 1992;9:1607-11
48. Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J 2009;11:250-61
49. Berezhkovskiy LM. On the possibility of self-induction of drug protein binding. J Pharm Sci 2010;99:4400-5
50. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994;56:248-52 (Pubitemid 24323915)
51. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34
52. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496-504
53. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: Facing up to complex realities. J Control Release 2010;141:265-76
54. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010;21:797-802
55. Pang KS, Durk MR. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn 2010;37:591-615
56. Qin S, Seo JW, Zhang H, et al. An imaging-driven model for liposomal stability and circulation. Mol Pharm 2010;7:12-21
57. Howell BA, Chauhan A. A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. J Pharm Sci 2010;99:3601-19
58. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/ PD) relationships: concepts and perspectives. Pharm Res 1999;16:176-85 (Pubitemid 29135119)
59. Gabrielsson J, Green AR, Van der Graaf PH. Optimising in vivo pharmacology studies-Practical PKPD considerations. J Pharmacol Toxicol Methods 2010;61:146-56
60. Berezhkovskiy LM. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects. J Pharm Sci 2011;100(6):2482-97
61. PBPK of Diazepam, IV and oral dosing. Available from: http://dougneubauer. com/pbpkdiazepam/ [Accessed 6 February 2011]